Bausch Current Deferred Revenue vs Cash And Equivalents Analysis
BHC Stock | USD 7.68 0.03 0.39% |
Bausch Health financial indicator trend analysis is way more than just evaluating Bausch Health Companies prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bausch Health Companies is a good investment. Please check the relationship between Bausch Health Current Deferred Revenue and its Cash And Equivalents accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bausch Health Companies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
Current Deferred Revenue vs Cash And Equivalents
Current Deferred Revenue vs Cash And Equivalents Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bausch Health Companies Current Deferred Revenue account and Cash And Equivalents. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Bausch Health's Current Deferred Revenue and Cash And Equivalents is 0.42. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Cash And Equivalents in the same time period over historical financial statements of Bausch Health Companies, assuming nothing else is changed. The correlation between historical values of Bausch Health's Current Deferred Revenue and Cash And Equivalents is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Bausch Health Companies are associated (or correlated) with its Cash And Equivalents. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Equivalents has no effect on the direction of Current Deferred Revenue i.e., Bausch Health's Current Deferred Revenue and Cash And Equivalents go up and down completely randomly.
Correlation Coefficient | 0.42 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Cash And Equivalents
Most indicators from Bausch Health's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bausch Health Companies current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bausch Health Companies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. At present, Bausch Health's Tax Provision is projected to decrease significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 0.30, whereas Issuance Of Capital Stock is forecasted to decline to 0.00.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 6.0B | 5.8B | 6.2B | 6.5B | Total Revenue | 8.4B | 8.1B | 8.8B | 9.2B |
Bausch Health fundamental ratios Correlations
Click cells to compare fundamentals
Bausch Health Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bausch Health fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 33.9B | 31.2B | 29.2B | 25.7B | 27.4B | 14.9B | |
Short Long Term Debt Total | 25.9B | 24.0B | 22.7B | 20.8B | 22.4B | 23.5B | |
Other Current Liab | 2.1B | 4.6B | 4.8B | 2.9B | 3.1B | 3.2B | |
Total Current Liabilities | 6.2B | 4.9B | 5.2B | 3.9B | 4.3B | 4.5B | |
Total Stockholder Equity | 1.1B | 535M | (106M) | (692M) | (1.0B) | (970.9M) | |
Property Plant And Equipment Net | 1.5B | 1.6B | 1.6B | 1.6B | 1.7B | 1.8B | |
Net Debt | 22.7B | 23.3B | 22.1B | 20.2B | 21.4B | 22.5B | |
Retained Earnings | (7.5B) | (8.0B) | (9.0B) | (9.2B) | (9.8B) | (9.3B) | |
Accounts Payable | 503M | 337M | 407M | 521M | 719M | 755.0M | |
Cash | 3.2B | 605M | 582M | 564M | 947M | 502.7M | |
Non Current Assets Total | 26.9B | 25.9B | 23.6B | 21.4B | 21.8B | 12.7B | |
Non Currrent Assets Other | 411M | 664M | 340M | 326M | 307M | 236.2M | |
Cash And Short Term Investments | 3.2B | 605M | 582M | 564M | 947M | 506.0M | |
Net Receivables | 1.8B | 1.6B | 1.8B | 1.8B | 2.0B | 2.1B | |
Common Stock Shares Outstanding | 352.1M | 355M | 358.9M | 362M | 364.9M | 246.3M | |
Liabilities And Stockholders Equity | 33.9B | 31.2B | 29.2B | 25.7B | 27.4B | 14.9B | |
Non Current Liabilities Total | 26.5B | 25.7B | 24.0B | 21.5B | 23.1B | 24.3B | |
Other Current Assets | 779M | 855M | 720M | 803M | 1.1B | 1.2B | |
Other Stockholder Equity | 429M | 454M | 462M | 159M | 214M | 203.3M | |
Total Liab | 32.7B | 30.6B | 29.2B | 25.4B | 27.4B | 28.8B | |
Property Plant And Equipment Gross | 1.5B | 1.6B | 3.4B | 3.5B | 3.8B | 4.0B | |
Total Current Assets | 7.0B | 5.3B | 5.6B | 4.2B | 5.6B | 5.9B | |
Accumulated Other Comprehensive Income | (2.1B) | (2.1B) | (1.9B) | (2.1B) | (1.9B) | (1.8B) | |
Short Term Debt | 1.2B | 52M | 49.9M | 482M | 450M | 472.5M | |
Intangible Assets | 10.2B | 8.4B | 6.9B | 5.8B | 6.5B | 5.8B | |
Inventory | 1.1B | 1.1B | 993M | 1.1B | 1.5B | 1.6B | |
Common Stock Total Equity | 10.2B | 10.2B | 10.3B | 10.4B | 11.9B | 7.0B | |
Common Stock | 10.2B | 10.2B | 10.3B | 10.4B | 10.4B | 6.1B | |
Other Liab | 1.6B | 1.5B | 1.2B | 967M | 1.1B | 1.3B | |
Current Deferred Revenue | 2.4B | (52M) | (49.9M) | 2.1B | 2.4B | 2.5B | |
Other Assets | 1.8B | 2.8B | 2.3B | 2.3B | 2.6B | 2.7B | |
Long Term Debt | 24.7B | 23.9B | 22.7B | 20.3B | 21.9B | 14.0B | |
Good Will | 13.1B | 13.0B | 12.5B | 11.5B | 11.2B | 7.2B | |
Property Plant Equipment | 1.5B | 1.6B | 1.6B | 1.8B | 2.1B | 2.2B | |
Net Tangible Assets | (22.3B) | (21.0B) | (19.5B) | (18.0B) | (16.2B) | (17.0B) | |
Noncontrolling Interest In Consolidated Entity | 73M | 70M | 72M | 952M | 1.1B | 1.1B | |
Retained Earnings Total Equity | (7.5B) | (8.0B) | (9.0B) | (9.2B) | (8.3B) | (7.9B) | |
Long Term Debt Total | 24.7B | 23.9B | 22.7B | 20.3B | 23.4B | 21.5B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Bausch Health Companies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bausch Health's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bausch Health Companies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bausch Health Companies Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bausch Health Companies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bausch Health. If investors know Bausch will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bausch Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.61) | Earnings Share (0.48) | Revenue Per Share 25.794 | Quarterly Revenue Growth 0.122 | Return On Assets 0.0415 |
The market value of Bausch Health Companies is measured differently than its book value, which is the value of Bausch that is recorded on the company's balance sheet. Investors also form their own opinion of Bausch Health's value that differs from its market value or its book value, called intrinsic value, which is Bausch Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bausch Health's market value can be influenced by many factors that don't directly affect Bausch Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bausch Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bausch Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bausch Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.